 |
 |
 |
 |
 |
 |
 |
|
 |
 |
Board and InvestorsGenstruct is backed by industry leading investors including Flagship Ventures and Pappas Ventures (formerly A.M. Pappas & Associates). Our vision for systems biology has been successfully implemented to create significant value within drug discovery.As managing partner and CEO of Flagship Ventures, Noubar Afeyan is a recognized technologist and entrepreneur, having founded and helped build several successful life science and technology startups during the past 19 years. Prior to Flagship, Dr. Afeyan participated in launching six highly successful new ventures. He was the founder, chairman and CEO of PerSeptive Biosystems (formerly Nasdaq: PBIO), a leader in the bio-instrumentation field. He also served as chairman of the Board of ChemGenics Pharmaceuticals, a privately held spin-off company of PerSeptive. After PerSeptive's acquisition by ABI, he was senior vice president and chief business officer of Applera, where he initiated and oversaw the creation of Celera Genomics (NYSE: CRA). Dr. Afeyan has also been a founding team member, investor, active board member, and advisor of Antigenics (Nasdaq: AGEN), Color Kinetics (Nasdaq: CLRK) and EXACT Sciences (Nasdaq: EXAS). Dr. Afeyan currently serves as a director for Flagship portfolio companies Affinnova, BG Medicine, Adnexus Therapeutics, Ensemble Discovery, Genstruct, Helicos BioSciences and Codon Devices, and for Antigenics and Color Kinetics. Dr. Afeyan is a senior lecturer at MIT in both the Sloan School of Management and the Biological Engineering Division. In addition, he is a member of the Board of Governors of Boston University Medical School, and he is a member of several advisory boards including MIT's Whitehead Institute and University of Pittsburgh's McGowan Institute for Regenerative Medicine. He is a founder/board member of an international economic development organization focusing on the former Soviet Republic of Armenia. Dr. Afeyan has authored numerous scientific publications and patents. He earned his Ph.D. in biochemical engineering from MIT. to top Art Pappas has over 30 years of experience as a pharmaceutical and biotechnology industry executive and venture capital investor in life science companies. Prior to founding Pappas Ventures in 1994, he held senior level positions at several multinational pharmaceutical companies. He was an executive member of the Board of Directors of Glaxo Holdings plc, for which he was responsible for international operations including research, development and manufacturing. Mr. Pappas previously was vice president of Commercial Operations for Abbott International Ltd., and he held various executive positions with Merrell Dow Pharmaceuticals and the Dow Chemical Company, in the United States and internationally. to top Mike Pavia is an Entrepreneur-in-Residence with Oxford Bioscience Partners. Prior to joining Oxford in 2002, he was chief technology officer at Millennium Pharmaceuticals, where his major focus was to improve the productivity of the drug discovery and development process through the appropriate use of new technologies. Dr. Pavia has 20 years experience in pharmaceutical research and discovery. He was formerly vice president for Cambridge Research at Sphinx Pharmaceuticals, a division of Eli Lilly & Co., focusing on the development of combinatorial chemistry technologies. Prior to Sphinx, Dr. Pavia held senior scientific positions in the Department of Chemistry at the Parke-Davis Pharmaceutical Research Division of Warner-Lambert. He holds a B.S. in chemistry from Lehigh University and a Ph.D. in organic chemistry from the University of Pennsylvania. to top Doug Lauffenburger is the director of the Biological Engineering [BE] Division, and professor at the Biology Department and Chemical Engineering Department at MIT. He is a member of the Center for Cancer Research, Center for Biomedical Engineering and Biotechnology Process Engineering Center as well as the Executive Committee of the MIT Computational & Systems Biology Initiative. Dr. Lauffenburger received his B.S. and Ph.D. in chemical engineering from the University of Illinois and the University of Minnesota respectively. His major research interests are in cell engineering, and central focus of his research program is in receptor-mediated cell communication and intracellular signal transduction, with emphasis on development of predictive computational models derived from quantitative experimental studies, and its application to drug discovery and development. Dr. Lauffenburger co-authored a monograph entitled “Receptors: Models for Binding, Trafficking & Signaling”, published by Oxford University Press. to top Jim Serum was previously the executive vice president and chief operating officer of Viaken Systems, a discovery informatics company. Dr. Serum co-founded Viaken after retiring from the Hewlett-Packard Company in 1999. Dr. Serum began his career at Hewlett-Packard in 1973 as an applications chemist in mass spectrometry. He held numerous R&D and Marketing management positions at Hewlett-Packard and in 1992 was named general manager for Mass Spectrometry, Infrared and Protein Chemical Systems. Dr. Serum was the founder of Hewlett-Packard's Bioscience Products business, and served as chairman of Hewlett-Packard's Pharmaceutical Business Council. Dr. Serum also served as co-chairman of the Hewlett-Packard Corporate R&D Council. He received a B.A. in chemistry from Hope College and a Ph.D. in organic chemistry from the University of Colorado. to top Jim Matheson has been a general partner of Flagship Ventures since 2000. He has previously served for 15 years as an officer and fighter pilot in the U.S. Navy. His duties included being stationed on aircraft carriers flying combat missions in Iraq and Bosnia, as a TOPGUN Instructor, and as the Officer-in-Charge of the Navy's West Coast adversary training and evaluation squadron. Mr. Matheson also gained broad experience in emerging weapons system design, testing and procurement, and was deeply involved in many of the Navy's modern IT initiatives. He continues to serve as a commander in the U.S. Naval Reserves. Mr. Matheson earned a B.S. with Honors in computer science from the U.S. Naval Academy and an M.B.A. from Harvard Business School. to top Keith Elliston is an experienced entrepreneur and intrapreneur who has dedicated his career to the development of leading-edge technology for drug discovery. Dr. Elliston spent over ten years with Merck Research Laboratories, where he served as the director of bioinformatics, and the scientific director of the Merck Gene Index project. He then joined Bayer Pharmaceuticals where he founded their global genomics and bioinformatics efforts, and was the section head of Genomics and the worldwide head of Bioinformatics. In 1997, Dr. Elliston joined Gene Logic as chief scientific officer and pioneered the development and application of molecular profiling to drug discovery. He was responsible for the development and management of six pharmaceutical research partnerships representing over $350 million in potential revenues. In 1999, Dr. Elliston founded Viaken Systems, where he was chairman, president and CEO. Dr. Elliston has been an advisor to Oak Investment Partners, Atlas Ventures and other biotechnology venture capital groups, and has participated in the early stage development of a number of successful biotech companies. Dr. Elliston received an M.S. in genetics from the University of Minnesota, and a Ph.D. in molecular genetics from Rutgers University. to top |
 |
|
 |
| One Alewife Center | Cambridge, MA 02140 | (617) 547-5421 | sitemap |